Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Fish oil and protein combo tested for COPD muscle loss

NCT ID NCT01624792

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether taking fish oil supplements (containing EPA and DHA) along with a protein drink could help people with COPD build muscle. Sixty-four participants took either fish oil or a placebo for four weeks. Researchers measured muscle protein synthesis to see if the combination improved muscle building.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Fish oil (eicosapentaenoic acid and docosahexaenoic acid) and protein (casein)
What this could lead to
If successful, this could point toward a nutritional strategy to help COPD patients maintain or gain muscle mass.
What could go wrong
This is a small, early-stage study with only 64 participants. The results may not apply to all COPD patients, and the effect on muscle mass may be minimal.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

64 people

The number who actually took part.

Started

Oct 2011

Finished

Jun 2016

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

45 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Inclusion criteria COPD subjects: * Ability to walk, sit down and stand up independently * Age 45 years or older * Ability to lay in supine or elevated position for 8 hours * Diagnosis of moderate to severe chronic airflow limitation, defined as measured forced expiratory volume in one second (FEV1) ≤ 70% of referen¬ce FEV1 * Clinically stable condition and not suffering from respiratory tract infection or exacerbation of their disease (defined as a combination of increased cough, sputum purulence, shortness of breath, systemic symptoms such as fever, and a decrease in FEV1 \> 10% compared with values when clinically stable in the preceding year) at least 4 weeks prior to the study * Shortness of breath on exertion * Willingness and ability to comply with the protocol, including: * Refraining from alcohol consumption (24 h) and intense physical activities (72h) prior to each study visit * Adhering to fasting state from 10 pm ± 2h onwards the day prior to each study visit Inclusion criteria healthy control subjects: * Healthy male or female according to the investigator's or appointed staff's judgment * Ability to walk, sit down and stand up independently * Age 45 years or older * Ability to lay in supine or elevated position for 8 hours * No diagnosis of COPD and forced expiratory volume in one second (FEV1) \> 80% of referen¬ce FEV1 * Willingness and ability to comply with the protocol, including: * Refraining from alcohol consumption (24 h) and intense physical activities (72h) prior to each study visit * Adhering to fasting state from 10 pm ± 2h onwards the day prior to each study visit Exclusion Criteria: * Any condition that may interfere with the definition 'healthy subject' according to the investigator's judgment (for healthy control group only) * Established diagnosis of malignancy * Established diagnosis of Diabetes Mellitus * History of untreated metabolic diseases including hepatic or renal disorder * Presence of acute illness or metabolically unstable chronic illness * Recent myocardial infarction (less than 1 year) * Any other condition according to the PI or study physicians would interfere with proper conduct of the study / safety of the patient * BMI ≥ 40 kg/m2 * Dietary or lifestyle characteristics: * Use of supplements containing EPA+DHA 3 months prior to the first test day Use of protein or amino acid containing nutritional supplements within 5 days of first study day * Current alcohol or drug abuse * Indications related to interaction with study products: * Known allergy to milk or milk products * Known hypersensitivity to fish and/or shellfish, Swanson EFAs Super EPA Fish oil or any of its ingredients, Swanson EFAs Certified Organic Extra Virgin Olive oil or any of its ingredients * Contraindications to biopsy procedure: * Platelet count (PLT) \< 100,000 * History of hypo- or hyper-coagulation disorders including use of a Coumadin derivative, history of deep venous thrombosis (DVT), or pulmonary embolism (PE) at any point in lifetime * Currently taking anti-thrombotics and cannot stop for 7 days (i.e. medical indication) * Allergy to local anesthetic * Use of long-term oral corticosteroids or short course of oral corticosteroids in the preceding month before enrollment * Failure to give informed consent or Investigator's uncertainty about the willingness or ability of the subject to comply with the protocol requirements

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic obstructive pulmonary disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Texas A&M University

    College Station, Texas, 77843, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.